Search Results 961-970 of 17063 for monoclonal antibody

1. A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults With Hypereosinophilic Syndrome (HES) - Mayo Clinic

   Participants with an allergy/ intolerance to a monoclonal antibody or biologic, or any of the excipients of the investigational product. Monoclonal antibodies ...

2. A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Patients With Kidney Transplant - Mayo Clinic

   To evaluate the efficacy of Cinryze® given for the treatment of acute antibody-mediated rejection (of renal allograft) (AMR) in kidney transplant recipients as ...

3. Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma - Mayo Clinic

   Monoclonal antibody; at least three half-lives since the last dose; Non-antibody immunotherapy (e.g., tumor vaccine); at least 42 days since last dose ...

4. A Study to Evaluate AMG 701 in Subjects with Multiple Myeloma - Mayo Clinic

   ... antibody in combination in the same line or separate lines of treatment OR refractory to PI, IMiD and CD38-directed antibody; Note: Subjects enrolled in the ...

5. Immune globulin-slra (intravenous route) - Mayo Clinic

   Description. Immune globulin-slra injection contains antibodies that make your immune system stronger. It is used for patients who have primary humoral ...

6. Cellular Responses to DNA Damage Induced by Topoisomerase Poisons - Anticancer Drug Action Laboratory - Mayo Clinic Research

   This enzyme is also the target of the anti-cancer drugs irinotecan, topotecan, MM398, PLX038 and CBX-12, along with a growing number of antibody-drug conjugates ...

7. X-linked agammaglobulinemia - Symptoms and causes - Mayo Clinic

   When these antibodies leave their systems, the babies begin to get repeat bacterial infections. ... People with the condition can't produce proteins called ...

8. A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma or non-Hodgkin Lymphoma - Mayo Clinic

   ... monoclonal antibodies or Chimeric Antigen Receptor (CAR) T-cell therapy; Patients with a chronic condition requiring the use of systemic corticosteroids at a ...

9. A Randomized Phase 3 Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients with Advanced Angiosarcoma (TAPPAS) - Mayo Clinic

   History of severe hypersensitivity reaction to any monoclonal antibody. Other severe acute or chronic medical (including bone marrow suppressive diseases) ...

10. A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma - Mayo Clinic

    Monoclonal antibody (ies). At least 28 days since the last dose of monoclonal antibody prior to first dose of tazemetostat. Immunotherapy (e.g., tumor vaccine).